Oriol Dols-Icardo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8453064/publications.pdf

Version: 2024-02-01

51 papers	3,176 citations	257357 24 h-index	214721 47 g-index
55 all docs	55 docs citations	55 times ranked	5917 citing authors

#	Article	IF	Citations
1	Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	1
2	Cortical microstructure in primary progressive aphasia: a multicenter study. Alzheimer's Research and Therapy, 2022, 14, 27.	3.0	10
3	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Molecular Neurodegeneration, 2022, 17, 29.	4.4	7
4	Smoking is associated with age at disease onset in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 97, 79-83.	1.1	2
5	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. Neurobiology of Aging, 2021, 99, 99.e15-99.e22.	1.5	8
6	Heterozygous APOE Christchurch in familial Alzheimerâ€™s disease without mutations in other Mendelian genes. Neuropathology and Applied Neurobiology, 2021, 47, 579-582.	1.8	10
7	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Network Open, 2021, 4, e211290.	2.8	12
8	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. Frontiers in Neurology, 2021, 12, 750543.	1.1	6
9	Calsyntenināŧ1 is a cerebrospinal fluid marker of frontotemporal dementiaâ€related synapse degeneration. Alzheimer's and Dementia, 2021, 17, .	0.4	1
10	Finding genetically-supported drug targets for Parkinsonâ€™s disease using Mendelian randomization of the druggable genome. Nature Communications, 2021, 12, 7342.	5.8	44
11	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2020, 87, 139.e1-139.e7.	1.5	35
12	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	54
13	Cortical microstructure in the amyotrophic lateral sclerosisâ€“frontotemporal dementia continuum. Neurology, 2020, 95, e2565-e2576.	1.5	19
14	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. Neurology, 2020, 95, e3288-e3302.	1.5	7
15	Oligodendroglial alterations in FTD caused by C9orf72 expansion. Alzheimer's and Dementia, 2020, 16, e040196.	0.4	0
16	Transcriptome characterization of the motor cortex suggests microglialâ€related key events due to TDPâ€43 aberrant inclusions. Alzheimer's and Dementia, 2020, 16, e042953.	0.4	0
17	Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. Scientific Reports, 2020, 10, 4308.	1.6	26
18	Genetic architecture of neurodegenerative dementias. Neuropharmacology, 2020, 168, 108014.	2.0	5

#	Article	IF	Citations
19	Assessing circular RNAs in Alzheimer's disease and frontotemporal lobar degeneration. Neurobiology of Aging, 2020, 92, 7-11.	1.5	30
20	Developmental Dynamic Dysphasia: Are Bilateral Brain Abnormalities a Signature of Inefficient Neural Plasticity?. Frontiers in Human Neuroscience, 2020, 14, 73.	1.0	4
21	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	4.9	1,414
22	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 597-609.	1.8	44
23	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	2.2	47
24	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
25	Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy. PLoS ONE, 2019, 14, e0212647.	1.1	2
26	HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. Neurobiology of Aging, 2019, 76, 215.e9-215.e14.	1.5	21
27	Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 162-168.	0.9	44
28	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032.	4.9	15
29	CSF sAPPÎ², YKL-40, and NfL along the ALS-FTD spectrum. Neurology, 2018, 91, e1619-e1628.	1.5	59
30	P1â€293: IDENTIFICATION OF EXOSOMAL MICRORNAS AS POTENTIAL DIAGNOSTIC BIOMARKERS FOR FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P398.	0.4	0
31	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	1.2	12
32	Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2018, 45, 220-231.	0.7	4
33	Cerebrospinal Fluid Anti-Amyloid-Î² Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. Journal of Alzheimer's Disease, 2016, 50, 1-7.	1.2	43
34	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. Journal of Alzheimer's Disease, 2016, 50, 539-546.	1.2	38
35	Assessing the role of TUBA4A gene in frontotemporal degeneration. Neurobiology of Aging, 2016, 38, 215.e13-215.e14.	1.5	9
36	MAPT H1 Haplotype is Associated with Late-Onset Alzheimerâ€™s Disease Risk in APOE É›4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. Journal of Alzheimer's Disease, 2015, 49, 343-352.	1.2	32

#	Article	IF	Citations
37	Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. Alzheimer Disease and Associated Disorders, 2015, 29, 353-356.	0.6	8
38	Effect of <scp>REST</scp> on brain metabolism in the Alzheimer disease continuum. Annals of Neurology, 2015, 78, 661-662.	2.8	2
39	Analysis of theCHCHD10gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Brain, 2015, 138, e400-e400.	3.7	56
40	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2014, 35, 444.e1-444.e4.	1.5	92
41	Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Human Molecular Genetics, 2014, 23, 749-754.	1.4	98
42	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 684-691.	0.9	55
43	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	3.9	93
44	P2-132: BIOMARKERS IN CEREBRAL AMYLOID ANGIOPATHY-RELATED INFLAMMATION. , 2014, 10, P519-P519.		0
45	Dissecting phenotypic traits linked to human resilience to Alzheimerâ€™s pathology. Brain, 2013, 136, 2510-2526.	3.7	294
46	MAPT H1 haplotype is associated with enhanced Î±-synuclein deposition in dementia with Lewy bodies. Neurobiology of Aging, 2013, 34, 936-942.	1.5	45
47	Analysis of theC9orf72Gene in Patients with Amyotrophic Lateral Sclerosis in Spain and Different Populations Worldwide. Human Mutation, 2013, 34, 79-82.	1.1	85
48	Comparison of 2 Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 469-476.	0.9	10
49	Rare Variants in Calcium Homeostasis Modulator 1 (CALHM1) Found in Early Onset Alzheimerâ€™s Disease Patients Alter Calcium Homeostasis. PLoS ONE, 2013, 8, e74203.	1.1	26
50	Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia. Neurobiology of Aging, 2012, 33, 1851.e17-1851.e19.	1.5	13
51	Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Movement Disorders, 2012, 27, 393-399.	2.2	144